Sanofi
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Olivier Charmeil
- Full Time Employees
- 82,878
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 54, Rue La BoEtie Paris France 75008
- IPO Date
- Jul 1, 2002
- CIK
- 0001121404
- Website
- sanofi.com
- Similar Companies
- Business
- Sanofi is a global biopharmaceutical leader involved in the exploration, development, manufacturing, and commercialization of diverse therapeutic solutions across various international markets. The company operates primarily through its focused segments of Pharmaceuticals and Vaccines, undergoing a strategic evolution to center on innovative biopharmaceutical advancements. Within its Pharmaceutical division, Sanofi delivers specialized care products, including advanced treatments for immunology, such as human monoclonal antibodies, and therapies addressing multiple sclerosis, other neurological conditions, inflammatory diseases, rare disorders, oncology, and specific rare blood conditions. The Vaccines segment remains a cornerstone, providing immunizations for diseases like poliomyelitis, pertussis, influenza, meningitis, and other booster and travel-related vaccines, serving populations globally. In a significant strategic realignment, Sanofi has moved to divest a controlling stake in its Consumer Healthcare unit, Opella, to intensify its focus on high-growth biopharma areas and enhance its research and development capabilities. The company generates revenue predominantly through the sale of its innovative pharmaceutical products and vaccines, complemented by income from licensing agreements, collaborations, and strategic partnerships. Its target market includes a broad spectrum of healthcare providers, such as hospitals, clinics, and pharmacies, alongside patients requiring specialized medical care. Recent initiatives highlight Sanofi's commitment to scientific breakthroughs, with substantial investments in research and development, particularly in immunology and oncology. Key developments include the acquisition of Inhibrx in early 2024 to bolster its rare disease pipeline, a collaboration with Orano Med in late 2024 for next-generation radioligand therapies in oncology, and the buyout of Vigil Neuroscience in May 2025. Furthermore, Sanofi Ventures committed additional capital in September 2025 to foster early-stage biotech and digital health innovations. Its robust pipeline currently features 93 clinical-stage projects, with 36 in Phase 3 or under regulatory review as of October 2025. The company also achieved a positive CHMP recommendation in November 2025 for Teizeild (teplizumab) for stage 2 type 1 diabetes in the European Union. Sanofi was established in 1973 and maintains its headquarters in Paris, France.
EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis
Sanofi Multiple Sclerosis Drug Gets EU Approval
Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia
Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First
Sanofi Wins FDA Nod for Expanded Use of T1D Drug in Children
Sanofi: Information concerning the total number of voting rights and shares – May 2026
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026
Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results
Sanofi ends Phase 3 riliprubart trial after weak interim results
Sanofi to Stop Late-Stage Study of Immune-Disorder Drug
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?